Puma Biotechnology shares surge 11.03% premarket after Q3 2025 earnings beat estimates by $0.12.

Puma Biotechnology (NASDAQ:PBYI) surged 11.03% in premarket trading following the release of its third-quarter 2025 earnings results, which showed a 278% beat on earnings per share estimates. The company reported stronger-than-expected revenue growth amid royalty income, driving analyst optimism about its financial trajectory. Recent upgrades from Wall Street Zen to a "Buy" rating and positive coverage of the earnings call highlights reinforced investor confidence. Additionally, the stock crossing above its 200-day moving average, a technical indicator often signaling bullish momentum, further amplified buying interest. These factors collectively contributed to the sharp premarket rise, reflecting renewed optimism about Puma’s earnings resilience and strategic performance.